🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

164 results for “Ars” Clear

  1. Drug COVID19-0001-USR

    United Therapeutics Europe Ltd

    SARS-CoV-2 Infection

    phase 2 small molecule active

    1 trial

  2. EPINEPHRINE NASAL SPRAY, Placebo Nasal Spray, EPINEPHRINE NASAL SPRAY

    Ars Pharmaceuticals Irl Limited

    Chronic Spontaneous Urticaria (CSU)

    phase 2 small molecule active

    1 trial

  3. GRAALL2014

    Pari Pharma GmbH

    Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

    phase 2 other active

    1 trial

  4. Hyperimmune plasma

    Lxo Ireland Designated Activity Company

    SARS-CoV 2

    phase 2 mab completed

    1 trial

  5. Lotilaner Gel, 2.0%

    Tarsus Pharmaceuticals

    Papulopustular Rosacea

    phase 2 small molecule completed

    1 trial

  6. Low Dose TP-05

    Tarsus Pharmaceuticals

    Healthy Volunteer

    phase 2 small molecule completed

    1 trial

  7. Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen

    China SXT Pharmaceuticals

    COVID-19

    phase 2 mab completed

    1 trial

  8. Placebo

    IRONWOOD PHARMACEUTICALS INC

    Functional Constipation in Children Ages 6-17 Years

    phase 2 small molecule completed

    1 trial

  9. Placebo

    Ars Pharmaceuticals Irl Limited

    Urticaria Chronic

    phase 2 small molecule active

    1 trial

  10. Placebo d'amiloride, AMILORIDE, AMILORIDE

    Pari Pharma GmbH

    Patients treated with lithium carbonate for a bipolar disorder treated for at least 5 years and with a urine concentration defect.

    phase 2 small molecule active

    1 trial

  11. RE-021 (Sparsentan)

    Travere Therapeutics

    Focal Segmental Glomerulosclerosis

    phase 2 small molecule completed

    1 trial

  12. REGN14256

    Regeneron UK Limited

    SARS-CoV-2

    phase 2 small molecule terminated

    1 trial

  13. SARS-CoV-2 convalescent plasma

    United Therapeutics Europe Ltd

    SARS-CoV 2

    phase 2 mab completed

    1 trial

  14. SARS-CoV-2 mRNA Vaccine ARCT-021

    Arcturus Therapeutics Holdings

    Hematopoietic and Lymphatic System Neoplasm

    phase 2 mab active

    1 trial

  15. SELPERCATINIB, SELPERCATINIB

    Ology Bioservices Ireland LTD

    Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.

    phase 2 small molecule active

    1 trial

  16. SIROLIMUS

    Pari Pharma GmbH

    Adult patients (men and women) (≥ 18 years of age) with cutaneous sarcoidosis involving the face

    phase 2 small molecule active

    1 trial

  17. Sparsentan

    Travere Therapeutics

    ANCA Associated Vasculitis

    phase 2 small molecule active

    1 trial

  18. Sparsentan_DF3, Sparsentan_DF2, Sparsentan_DF4

    Travere Therapeutics

    Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)

    phase 2 small molecule active

    1 trial

  19. TAK-019

    Takeda Pharmaceuticals International AG

    Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

    phase 2 mab completed

    1 trial

  20. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

    phase 2 small molecule completed

    1 trial

  21. TP-03

    Tarsus Pharmaceuticals

    Meibomian Gland Dysfunction

    phase 2 small molecule completed

    1 trial

  22. TP-05 (lotilaner) Low Dose

    Tarsus Pharmaceuticals

    Lyme Disease

    phase 2 small molecule active

    1 trial

  23. TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, PERTUZUMAB, TRASTUZUMAB EMTANSINE

    Cancer Prevention Pharma (Ireland) Limited

    Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy

    phase 2 small molecule active

    1 trial

  24. Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

    SINOVAC BIOTECH LTD

    COVID-19

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources